[{"id":"5aa1495f-1183-4095-b05a-503274e48528","acronym":"","url":"https://clinicaltrials.gov/study/NCT04936529","created_at":"2021-06-23T17:52:37.826Z","updated_at":"2025-02-25T13:53:51.961Z","phase":"Phase 2","brief_title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","source_id_and_acronym":"NCT04936529","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • MYCN • CSF2","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 286","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2025-02-20"},{"id":"5949ed40-8066-4fa3-b731-56d11b1c4969","acronym":"MRT-2359-001","url":"https://clinicaltrials.gov/study/NCT05546268","created_at":"2022-09-19T13:55:51.266Z","updated_at":"2025-02-25T14:17:16.661Z","phase":"Phase 1/2","brief_title":"Study of Oral MRT-2359 in Selected Cancer Patients","source_id_and_acronym":"NCT05546268 - MRT-2359-001","lead_sponsor":"Monte Rosa Therapeutics, Inc","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN amplification • MYC expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • MRT-2359"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-17"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"149819dc-f2ee-4b82-83e1-8c607402853f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909777","created_at":"2021-01-18T14:16:53.862Z","updated_at":"2025-02-25T14:50:16.761Z","phase":"Phase 1","brief_title":"Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma","source_id_and_acronym":"NCT02909777","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN","pipe":" | ","alterations":" MYCN expression","tags":["MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fimepinostat (CUDC-907)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-13"},{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"7246a629-768b-4557-b16c-b951baaa4ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742258","created_at":"2021-01-18T18:19:49.340Z","updated_at":"2025-02-25T15:34:14.094Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03742258","lead_sponsor":"Northwestern University","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 12/19/2028","study_completion_date":" 12/19/2028","last_update_posted":"2025-02-11"},{"id":"302e12e8-3d06-4205-8871-3fc4c45bd55f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01856192","created_at":"2021-01-18T08:17:29.922Z","updated_at":"2025-02-25T16:43:43.231Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT01856192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MYC • CD20 • CD4","pipe":" | ","alterations":" CD20 expression • MYC translocation","tags":["ALK • MYC • CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"683d44c3-486a-4d73-b201-dfcc60cc1610","acronym":"KEYNOTE-B47","url":"https://clinicaltrials.gov/study/NCT04130516","created_at":"2021-01-18T20:10:38.993Z","updated_at":"2025-02-25T16:09:34.811Z","phase":"Phase 1/2","brief_title":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab","source_id_and_acronym":"NCT04130516 - KEYNOTE-B47","lead_sponsor":"Linnaeus Therapeutics, Inc.","biomarkers":" PD-L1 • MYC","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LNS8801"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/21/2019","start_date":" 10/21/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2024-12-13"},{"id":"da2a1d36-30db-440a-9df5-123b9dec43a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06502249","created_at":"2025-02-27T07:46:28.341Z","updated_at":"2025-02-27T07:46:28.341Z","phase":"","brief_title":"Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)","source_id_and_acronym":"NCT06502249","lead_sponsor":"Ain Shams University","biomarkers":" MYC • IL6 • STAT3 • HSP90AA1","pipe":"","alterations":" ","tags":["MYC • IL6 • STAT3 • HSP90AA1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2026","start_date":" 06/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-07-16"},{"id":"8e23dfed-66db-4dea-b013-38aff34edc35","acronym":"NCI-2015-00960","url":"https://clinicaltrials.gov/study/NCT02427620","created_at":"2021-01-17T17:51:13.234Z","updated_at":"2024-07-02T16:34:36.739Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT02427620 - NCI-2015-00960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • CD20","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • MYC • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-10"},{"id":"7026c02a-02d2-4eaf-9842-da3071018ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02443077","created_at":"2021-01-18T11:42:20.749Z","updated_at":"2024-07-02T16:34:37.048Z","phase":"Phase 3","brief_title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02443077","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1","pipe":" | ","alterations":" CD79A mutation + CD79B mutation","tags":["MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 05/10/2025","primary_completion_date":" 05/10/2025","study_txt":" Completion: 05/10/2025","study_completion_date":" 05/10/2025","last_update_posted":"2024-06-07"},{"id":"ef515d3d-d584-4ab7-90a2-1415e247bfbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04442022","created_at":"2021-01-18T21:22:49.510Z","updated_at":"2024-07-02T16:34:38.119Z","phase":"Phase 2/3","brief_title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04442022","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone"],"overall_status":"Recruiting","enrollment":" Enrollment 501","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-05"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"700dc8c9-7994-4f0c-9f97-a10c4b36a1dd","acronym":"GO43075","url":"https://clinicaltrials.gov/study/NCT04980222","created_at":"2021-07-28T19:52:29.789Z","updated_at":"2024-07-02T16:34:58.915Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04980222 - GO43075","lead_sponsor":"Hoffmann-La Roche","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • MYC expression • BCL6 translocation","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC expression • BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-04"},{"id":"db5fc24c-f27b-49ea-89fd-c21be640542e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311958","created_at":"2021-01-18T16:21:30.638Z","updated_at":"2024-07-02T16:34:59.289Z","phase":"Phase 1","brief_title":"Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance","source_id_and_acronym":"NCT03311958","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MYC","pipe":" | ","alterations":" MYC translocation","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 01/26/2024","primary_completion_date":" 01/26/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-06-04"},{"id":"2d189d8c-95d4-4063-96bb-7adb6463bde6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06249191","created_at":"2024-02-08T15:19:53.031Z","updated_at":"2024-07-02T16:34:59.457Z","phase":"Phase 1/2","brief_title":"Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT06249191","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" MYC","pipe":"","alterations":" ","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-06-03"},{"id":"fae84839-338f-451e-a552-ea4530e69d00","acronym":"UKALL14","url":"https://clinicaltrials.gov/study/NCT01085617","created_at":"2021-01-18T04:16:52.338Z","updated_at":"2024-07-02T16:35:04.439Z","phase":"Phase 3","brief_title":"Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01085617 - UKALL14","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • MYC","pipe":" | ","alterations":" MYC translocation • Chr t(4;11)(q21;q23)","tags":["ABL1 • BCR • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation • Chr t(4;11)(q21;q23)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • imatinib • cytarabine • cyclophosphamide • etoposide IV • vincristine • daunorubicin • melphalan • Oncaspar liquid (pegaspargase) • fludarabine IV • nelarabine • mercaptopurine • Kepivance (palifermin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1033","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-10"},{"id":"050cad85-632c-4a3d-8dc0-6b7c173500dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796884","created_at":"2023-10-19T11:12:17.673Z","updated_at":"2024-07-02T16:35:06.193Z","phase":"Phase 2","brief_title":"Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer","source_id_and_acronym":"NCT03796884","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" MYC • PCNA • AXIN1","pipe":" | ","alterations":" PCNA expression","tags":["MYC • PCNA • AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PCNA expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 10/30/2019","start_date":" 10/30/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-03"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"5d576388-a550-4b35-b698-5134873cd7dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03793140","created_at":"2021-01-18T18:45:13.009Z","updated_at":"2024-07-02T16:35:08.385Z","phase":"Phase 2","brief_title":"A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations","source_id_and_acronym":"NCT03793140","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bylantra (devimistat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/31/2018","start_date":" 12/31/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-22"},{"id":"defc9de3-2fea-4a63-992f-0da7e4f79121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04594798","created_at":"2021-01-19T20:29:12.188Z","updated_at":"2024-07-02T16:35:09.366Z","phase":"Phase 2","brief_title":"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL","source_id_and_acronym":"NCT04594798","lead_sponsor":"University of Rochester","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-16"},{"id":"bb4e6c88-c7d9-42ab-942f-08dd0a63585b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06357338","created_at":"2024-04-10T17:42:48.293Z","updated_at":"2024-07-02T16:35:10.258Z","phase":"","brief_title":"Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma","source_id_and_acronym":"NCT06357338","lead_sponsor":"Marwa Mahmoud Hassan","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 70","initiation":"Initiation: 03/19/2024","start_date":" 03/19/2024","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-04-10"},{"id":"945e49ad-157e-4566-89d3-6b4ba4498abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04696029","created_at":"2021-01-19T20:49:35.193Z","updated_at":"2024-07-02T16:35:10.980Z","phase":"Phase 2","brief_title":"DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma","source_id_and_acronym":"NCT04696029","lead_sponsor":"Giselle Sholler","biomarkers":" TP53 • MYC • MYCN","pipe":" | ","alterations":" TP53 mutation • MYCN amplification • TP53 amplification","tags":["TP53 • MYC • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MYCN amplification • TP53 amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-04-08"}]